Price Alert

Xeris Biopharma Inc. (XERS)

NASDAQ: XERS · Real-Time Price · USD

7.85

-0.04 (-0.51%)

At close: Sep 05, 2025, 3:59 PM

7.86

0.13%

After-hours: Sep 05, 2025, 07:49 PM EDT

Xeris Biopharma Statistics

Share Statistics

Xeris Biopharma has 161.48M shares outstanding. The number of shares has increased by 7.49% in one year.

Shares Outstanding	161.48M
Shares Change (YoY)	7.49%
Shares Change (QoQ)	4.04%
Owned by Institutions (%)	56.94%
Shares Floating	149.84M
Failed to Deliver (FTD) Shares	4,723
FTD / Avg. Volume	0.19%

Short Selling Information

The latest short interest is 13.35M, so 8.27% of the outstanding shares have been sold short.

Short Interest	13.35M
Short % of Shares Out	8.27%
Short % of Float	8.6%
Short Ratio (days to cover)	2.91

Valuation Ratios

The PE ratio is -9.07 and the forward PE ratio is 31.36. Xeris Biopharma's PEG ratio is 0.51.

PE Ratio	-9.07
Forward PE	31.36
PS Ratio	2.45
Forward PS	3.7
PB Ratio	-16.8
P/FCF Ratio	-13.15
PEG Ratio	0.51

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Xeris Biopharma.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.67, with a Debt / Equity ratio of -9.17.

Current Ratio	1.67
Quick Ratio	1.19
Debt / Equity	-9.17
Debt / EBITDA	-19.4
Debt / FCF	-7.17
Interest Coverage	-1.01

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$515.41K
Profits Per Employee	$-139.18K
Employee Count	394
Asset Turnover	0.63
Inventory Turnover	0.76

Taxes

Income Tax	-2.27M
Effective Tax Rate	3.97%

Stock Price Statistics

The stock price has increased by 211.86% in the last 52 weeks. The beta is 0.86, so Xeris Biopharma's price volatility has been higher than the market average.

Beta	0.86
52-Week Price Change	211.86%
50-Day Moving Average	6.06
200-Day Moving Average	4.59
Relative Strength Index (RSI)	74.3
Average Volume (20 Days)	2,437,016

Income Statement

In the last 12 months, Xeris Biopharma had revenue of 203.07M and earned -54.84M in profits. Earnings per share was -0.37.

Revenue	203.07M
Gross Profit	166.24M
Operating Income	-33.65M
Net Income	-54.84M
EBITDA	-13.99M
EBIT	-26.62M
Earnings Per Share (EPS)	-0.37

Full Income Statement

Balance Sheet

The company has 71.62M in cash and 271.45M in debt, giving a net cash position of -199.83M.

Cash & Cash Equivalents	71.62M
Total Debt	271.45M
Net Cash	-199.83M
Retained Earnings	-671.86M
Total Assets	334.69M
Working Capital	90.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -36.98M and capital expenditures -868K, giving a free cash flow of -37.85M.

Operating Cash Flow	-36.98M
Capital Expenditures	-868K
Free Cash Flow	-37.85M
FCF Per Share	-0.26

Full Cash Flow Statement

Margins

Gross margin is 81.86%, with operating and profit margins of -16.57% and -27%.

Gross Margin	81.86%
Operating Margin	-16.57%
Pretax Margin	-28.12%
Profit Margin	-27%
EBITDA Margin	-6.89%
EBIT Margin	-16.57%
FCF Margin	-18.64%

Dividends & Yields

XERS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for XERS is $8.5, which is 7.7% higher than the current price. The consensus rating is "Buy".

Price Target	$8.5
Price Target Difference	7.7%
Analyst Consensus	Buy
Analyst Count	6

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	0.24
Piotroski F-Score	4